exp3174 and valsartan
exp3174 has been researched along with valsartan in 22 studies
Compound Research Comparison
| Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (valsartan) | Trials (valsartan) | Recent Studies (post-2010) (valsartan) |
|---|---|---|---|---|---|
| 236 | 29 | 43 | 3,577 | 871 | 2,140 |
Protein Interaction Comparison
| Protein | Taxonomy | exp3174 (IC50) | valsartan (IC50) |
|---|---|---|---|
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0027 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0023 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0074 |
Research
Studies (22)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 13 (59.09) | 29.6817 |
| 2010's | 4 (18.18) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR | 1 |
| Schieffer, B; Schmidt, B | 1 |
| Berellini, G; Cruciani, G; Mannhold, R | 1 |
| Giridhar, R; Murumkar, P; Naik, P; Yadav, MR | 1 |
| Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T | 1 |
| Abad-Santos, F; Cabaleiro, T; López-Rodríguez, R; Novalbos, J; Ochoa, D; Prieto-Pérez, R; Román, M; Talegón, M; Wojnicz, A | 1 |
| Bauer, JH; Reams, GP | 1 |
| Coca, A; Giner, V | 1 |
| Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR | 1 |
| Buczko, W; Chabielska, E; Chłopicki, S; Gryglewski, RJ; Koda, M | 1 |
| Buczko, W; Chabielska, E; Kalinowski, L; Malinski, T; Matys, T | 1 |
| Edvinsson, L; Malmsjö, M; Pantev, E; Stenman, E; Wackenfors, A | 1 |
| Boonstra, PW; Buikema, H; Lübeck, RH; van Buiten, A; van Gilst, WH; van Veldhuisen, DJ; Voors, AA; Wagenaar, LJ | 1 |
| Bessard, G; Caron, F; Cracowski, JL; Hakim, A; Hoffmann, P; Sessa, C; Stanke-Labesque, F | 1 |
| Dominiak, P; Häuser, W | 1 |
| Buczko, W; Chabielska, E; Domaniewski, T; Kucharewicz, I; Matys, T; Pawlak, R | 1 |
| Avery, MA; Benson, SC; Chittiboyina, A; Desai, P; Ho, CI; Kurtz, TW; Pershadsingh, HA; Pravenec, M; Qi, N; Wang, J | 1 |
| Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM | 1 |
| Koyabu, N; Kuwano, M; Murakami, H; Nakamura, T; Ohtani, H; Satoh, H; Sawada, Y; Tsujimoto, M; Uchiumi, T; Ushigome, F; Yamashita, F | 1 |
| Arsenault, J; Cabana, J; Escher, E; Guillemette, G; Lanthier, L; Lavigne, P; Leduc, R; Lehoux, J | 1 |
| Bester, K; Kisielius, V; Li, R; Liang, C; Svendsen, SB | 1 |
| Alfarraj, S; Alharbi, SA; Almoallim, HS; Ansari, MJ; Dar, AA; Dar, SA; Hassan, GI; Jan, I; Khan, NA; Mir, KB; Raina, A; Sofi, JA; Tarique, M; Wani, TA; Wani, TU | 1 |
Reviews
6 review(s) available for exp3174 and valsartan
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Growth Hormone; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Thromboxane A2 | 2003 |
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan | 2010 |
The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
Topics: Acrylates; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Losartan; Pyridines; Quinolines; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 1995 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1999 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2004 |
Other Studies
16 other study(ies) available for exp3174 and valsartan
| Article | Year |
|---|---|
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Structure-Activity Relationship; Tetrazoles | 2005 |
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents | 2011 |
Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Topics: Alleles; Angiotensin Receptor Antagonists; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Female; Half-Life; Humans; Male; Polymorphism, Genetic; Reference Values; Sex Factors | 2013 |
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan | 2000 |
Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition.
Topics: Antihypertensive Agents; Blood Platelets; Collagen; Humans; Imidazoles; Losartan; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thromboxane; Tetrazoles; Thromboxane-A Synthase; Valine; Valsartan | 2000 |
Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.
Topics: Angiotensin Receptor Antagonists; Blood Platelets; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Imidazoles; Kinetics; Losartan; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2002 |
Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Base Sequence; Benzimidazoles; Biphenyl Compounds; Coronary Vessels; Culture Techniques; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Losartan; Male; Middle Aged; Molecular Sequence Data; Probability; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2002 |
Functional antagonism of different angiotensin II type I receptor blockers in human arteries.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Humans; Imidazoles; In Vitro Techniques; Losartan; Mammary Arteries; Muscle Contraction; Muscle, Smooth, Vascular; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2002 |
Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Antagonism; Humans; Imidazoles; In Vitro Techniques; Irbesartan; Losartan; Muscle Contraction; Muscle, Smooth, Vascular; Receptors, Thromboxane A2, Prostaglandin H2; Saphenous Vein; Tetrazoles; Valine; Valsartan | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan | 2003 |
Nitric oxide-dependent antiplatelet action of AT1-receptor antagonists in a pulmonary thromboembolism in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Imidazoles; Injections, Intraperitoneal; Losartan; Mice; Platelet Aggregation Inhibitors; Pulmonary Embolism; Rats; Tetrazoles; Valine; Valsartan | 2003 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Cell Differentiation; Cells, Cultured; Chlorocebus aethiops; Drug Evaluation, Preclinical; Gene Expression Regulation; Imidazoles; Insulin; Irbesartan; Losartan; Male; Mice; Models, Molecular; Myoblasts; Protein Conformation; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Telmisartan; Tetrazoles; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Triglycerides; Valine; Valsartan; Weight Gain | 2004 |
Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.
Topics: Acetates; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biological Transport; Biphenyl Compounds; Blotting, Western; Cell Line; Chromones; Cyclopropanes; Dose-Response Relationship, Drug; Estrone; Humans; Imidazoles; Indoles; Leukotriene Antagonists; Losartan; Molecular Structure; Organic Anion Transporters, Sodium-Independent; Phenylcarbamates; Quinolines; Structure-Activity Relationship; Sulfides; Sulfonamides; Tetrazoles; Tosyl Compounds; Transfection; Tritium; Valine; Valsartan | 2006 |
A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Topics: Alanine; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Chlorocebus aethiops; COS Cells; Humans; Imidazoles; Inositol Phosphates; Irbesartan; Losartan; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Telmisartan; Tetrazoles; Threonine; Valine; Valsartan | 2010 |
Sartan blood pressure regulators in classical and biofilm wastewater treatment - Concentrations and metabolism.
Topics: Angiotensin II Type 1 Receptor Blockers; Biofilms; Blood Pressure; Humans; Irbesartan; Losartan; Sewage; Valsartan; Wastewater; Water Pollutants, Chemical; Water Purification | 2023 |
Simultaneous quantification of losartan potassium and its active metabolite, EXP3174, in rabbit plasma by validated HPLC-PDA.
Topics: Animals; Chromatography, High Pressure Liquid; Losartan; Quality Control; Rabbits; Reproducibility of Results; Valsartan | 2023 |